Literature DB >> 6284653

The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.

M Limbert, G Seibert, E Schrinner.   

Abstract

Desacetyl-cefotaxime, the main metabolite of cefotaxime, possesses a broad antibacterial spectrum. Its activity is lower than that of cefotaxime, but significantly surpasses that of cefazolin against gram-negative bacteria. The beta-lactamase stability of desacetyl-cefotaxime is higher than that of the parent compound. This beta-lactamase stability might be responsible for the synergistic effects of cefotaxime and desacetyl-cefotaxime occasionally seen in in vitro combination studies.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6284653     DOI： 10.1007/bf01816732

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  11 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Comparison of techniques for measurement of in vitro antibiotic synergism.

Authors:  C W Norden; H Wentzel; E Keleti
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

3.  Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins.

Authors:  C H O'Callaghan; P W Muggleton; G W Ross
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

4.  Management of severe systemic infections caused by multiple resistant organisms.

Authors:  P M Shah; E B Helm; W Stille
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro and in vivo).

Authors:  E Schrinner; M Limbert; L Penasse; A Lutz
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

6.  The evaluation of efficacy and safety of cefotaxime: a review of 2500 cases.

Authors:  J P Young; J M Husson; K Bruch; R J Blomer; C Savopoulos
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

7.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

8.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

9.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

10.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191
View more
  9 in total

1.  Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.

Authors:  G Piédrola; I Galan; A Leyva; M C Maroto
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Delivery of cefotaxime to the brain via intranasal administration.

Authors:  Prashanth Manda; Jamie K Hargett; Siva Ram Kiran Vaka; Michael A Repka; S Narasimha Murthy
Journal:  Drug Dev Ind Pharm       Date:  2011-06-27       Impact factor: 3.225

Review 3.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

4.  A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment.

Authors:  Matthieu Grégoire; Florian Berteau; Ronan Bellouard; Quentin Lebastard; Philippe Aubert; Jacques Gonzales; François Javaudin; Anne Bessard; Pascale Bemer; Éric Batard; Didier Lepelletier; Michel Neunlist; Emmanuel Montassier; Éric Dailly
Journal:  Comput Struct Biotechnol J       Date:  2021-03-04       Impact factor: 7.271

5.  In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

Authors:  K Oizumi; I Hayashi; S Aonuma; K Konno
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.

Authors:  F Vallée; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

8.  Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.

Authors:  K L Heim; C E Halstenson; C M Comty; M B Affrime; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.

Authors:  S G Jenkins; J W Lewis
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.